Quick Answer
Voyager Therapeutics, Inc. reported Cash and Equivalents of $65.30 million for fiscal year 2025.
Voyager Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $65.30M | -8.5% |
| 2024 | $71.37M | +3.7% |
| 2023 | $68.80M | -30.5% |
| 2022 | $98.96M | -15.7% |
| 2021 | $117.43M | +12.4% |
| 2020 | $104.44M | +21.4% |
| 2019 | $86.04M | +83.6% |
| 2018 | $46.86M | +48.6% |
| 2017 | $31.53M | -13.9% |
| 2016 | $36.64M | +17.0% |
| 2015 | $31.31M | +345.0% |
| 2014 | $7.04M | +5111.1% |
| 2013 | $135.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $45.12M | -59.9% | +2.7% |
| June 30, 2025 | $43.94M | -42.3% | -41.2% |
| March 31, 2025 | $74.75M | -47.8% | +4.7% |
| December 31, 2024 | $71.37M | +3.7% | -36.6% |
| September 30, 2024 | $112.53M | +72.4% | +47.8% |
| June 30, 2024 | $76.13M | -68.8% | -46.8% |
| March 31, 2024 | $143.08M | -46.7% | +108.0% |
| December 31, 2023 | $68.80M | -30.5% | +5.4% |
- Voyager Therapeutics, Inc. showed a decrease of -8.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, Voyager Therapeutics, Inc.’s cash and equivalents has grown by 48270.4% (from $135.0 thousand to $65.30 million).
- The most recent figure is from Voyager Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: